Metsera saga continues, with upped bids from Novo and Pfizer
The bidding war for US obesity focused biotech Metsera (Nasdaq: MTSR), which has attracted offers from Pfizer (NYSE: PFE) and Novo Nordisk (NOV: N), and resulted in lawsuits by the US pharma giant taking legal action against the Danish firm and Metsera, has taken a further step.
Today, Novo Nordisk confirmed that it has submitted an updated, unsolicited proposal to acquire Metsera. The updated proposal has been declared superior by Metsera’s board of directors.
The acquisition of Metsera, including its early and development-stage incretin and non-incretin analogue peptide programs, would provide Novo Nordisk the opportunity to maximise the potential of Metsera’s complementary portfolio and capabilities. An acquisition would be in line with Novo Nordisk’s long-term strategy of developing innovative and differentiated medicines and treating millions more people living with obesity and diabetes and their associated comorbidities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze